Literature DB >> 27190913

Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Staging of Bladder Cancer.

Elham Rabie1, Fariborz Faeghi2, Mohammad-Hossein Izadpanahi3, Mohammad-Ali Dayani4.   

Abstract

INTRODUCTION: Dynamic Contrast Enhanced (DCE)-Magnetic Resonance Imaging (MRI) is a useful technique in which rapid enhancement of tumour by uptake of the contrast agent compared to bladder wall. AIM: To evaluate the accuracy of dynamic gadolinium-enhanced MRI in staging of bladder cancer through differentiating superficial tumours from invasive tumours and organ-confined tumours from non-organ-confined tumours. In addition, the benefits of DCE-MRI in diagnosis of tumour progression steps were investigated.
MATERIALS AND METHODS: This was a quasi-experimental study in which 45 patients (95.55% men and 4.45% women) were enrolled. Patients with confirmed transitional cell carcinoma by histopathology findings were imaged using 1.5 Tesla MRI systems. Pathology results were considered as the standard reference. Tumour stage was determined by imaging findings and compared with pathologic findings after radical cystectomy. Data were analysed by SPSS version 16 and the level of significance in all tests was considered p<0.001.
RESULTS: The most common stage that was seen in pathology and MRI findings was T3b. Kappa agreement coefficient between MRI and pathology was 0.7 (p<0.001). The accuracy of MRI in differentiating superficial tumours (≤T1) from invasive tumours (≥ T2a), and organ-confined tumours (≤T2b) from non-organ-confined tumours (≥T3b) was 0.97 and 0.84, respectively. The overall accuracy of MRI was 0.77 (p<0.001). Totally, 10 cases of disagreement between MRI and pathological staging were found, eight (80%) of which were overestimated and two cases (20%) underestimated. MRI detection rate was 0% in stage Ta, 100% in stage T1, 66.7% in stage T2, 86.7% in stage T3, and 100% in stage T4. The sensitivity and specificity of MRI in differentiating superficial tumours from invasive tumours were 0.97 and 1, respectively, and in differentiating organ-confined tumours from non-organ-confined tumours were 0.94 and 0.77, respectively. The Spearman's correlation coefficient between the signal enhancement slope of time-intensity curves and tumour stages was 0.88 (p<0.001).
CONCLUSION: Gadolinium-enhanced MRI is an appropriate and useful modality with a high accuracy in determining the stage of the bladder cancer. In addition, this method shows extension and progression of tumour and tumour invasion depth.

Entities:  

Keywords:  Bladder Neoplasms; DCE-MRI; Neoplasm staging

Year:  2016        PMID: 27190913      PMCID: PMC4866211          DOI: 10.7860/JCDR/2016/17596.7690

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  23 in total

Review 1.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Authors:  M Craig Hall; Sam S Chang; Guido Dalbagni; Raj Som Pruthi; John Derek Seigne; Eila Curlee Skinner; J Stuart Wolf; Paul F Schellhammer
Journal:  J Urol       Date:  2007-12       Impact factor: 7.450

2.  Gadolinium-enhanced magnetic resonance imaging in the staging of urinary bladder neoplasms.

Authors:  M Sohn; J Neuerburg; F Teufl; K Bohndorf
Journal:  Urol Int       Date:  1990       Impact factor: 2.089

Review 3.  Tumor angiogenesis: tutorial on implications for imaging.

Authors:  T J Passe; D A Bluemke; S S Siegelman
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

4.  Value of MRI in local staging of bladder cancer.

Authors:  Mahyar Ghafoori; Madjid Shakiba; Atefeh Ghiasi; Nazanin Asvadi; Kamal Hosseini; Manijeh Alavi
Journal:  Urol J       Date:  2013       Impact factor: 1.510

5.  MR staging of bladder carcinoma: correlation with pathologic findings.

Authors:  J N Buy; A A Moss; C Guinet; M A Ghossain; L Malbec; L Arrive; D Vadrot
Journal:  Radiology       Date:  1988-12       Impact factor: 11.105

6.  Bladder cancer: evaluation of staging accuracy using dynamic MRI.

Authors:  A Rajesh; H K Sokhi; R Fung; K A Mulcahy; M J G Bankart
Journal:  Clin Radiol       Date:  2011-09-14       Impact factor: 2.350

7.  Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging.

Authors:  B Kim; R C Semelka; S M Ascher; D B Chalpin; P R Carroll; H Hricak
Journal:  Radiology       Date:  1994-10       Impact factor: 11.105

8.  Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure.

Authors:  John P Stein; Donald G Skinner
Journal:  World J Urol       Date:  2006-03-04       Impact factor: 4.226

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

Review 10.  Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer.

Authors:  Ramy F Youssef; Yair Lotan
Journal:  ScientificWorldJournal       Date:  2011-02-14
View more
  11 in total

1.  Novel contrast mixture improves bladder wall contrast for visualizing bladder injury.

Authors:  Pradeep Tyagi; Joseph J Janicki; T Kevin Hitchens; Lesley M Foley; Mahendra Kashyap; Naoki Yoshimura; Jonathan Kaufman
Journal:  Am J Physiol Renal Physiol       Date:  2017-03-29

2.  Recent Developments in Imaging in BPS/IC.

Authors:  Teruyuki Ogawa; Pradeep Tyagi; Osamu Ishizuka; Tomohiro Ueda; Michael B Chancellor; Christopher J Chermansky; Naoki Yoshimura
Journal:  Curr Bladder Dysfunct Rep       Date:  2019-12-14

3.  Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond.

Authors:  Pradeep Tyagi; Joseph Janicki; Chan-Hong Moon; Jonathan Kaufman; Christopher Chermansky
Journal:  Int Urol Nephrol       Date:  2018-02-01       Impact factor: 2.370

Review 4.  Imaging in Localized Bladder Cancer: Can Current Diagnostic Modalities Provide Accurate Local Tumor Staging?

Authors:  Sandeep Gurram; Akhil Muthigi; Jillian Egan; Lambros Stamatakis
Journal:  Curr Urol Rep       Date:  2019-11-28       Impact factor: 3.092

5.  Diffusion kurtosis imaging to assess correlations with clinicopathologic factors for bladder cancer: a comparison between the multi-b value method and the tensor method.

Authors:  Fang Wang; Hai-Ge Chen; Rui-Yun Zhang; Di Jin; Shuai-Shuai Xu; Guang-Yu Wu; Jian-Rong Xu
Journal:  Eur Radiol       Date:  2019-01-21       Impact factor: 5.315

Review 6.  Recent advances in imaging and understanding interstitial cystitis.

Authors:  Pradeep Tyagi; Chan-Hong Moon; Joseph Janicki; Jonathan Kaufman; Michael Chancellor; Naoki Yoshimura; Christopher Chermansky
Journal:  F1000Res       Date:  2018-11-09

Review 7.  Role of magnetic resonance imaging in tumor staging and follow-up for bladder cancer.

Authors:  Ki Choon Sim; Deuk Jae Sung
Journal:  Transl Androl Urol       Date:  2020-12

8.  Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images.

Authors:  Yubing Tong; Jayaram K Udupa; Chuang Wang; Jerry Chen; Sriram Venigalla; Thomas J Guzzo; Ronac Mamtani; Brian C Baumann; John P Christodouleas; Drew A Torigian
Journal:  Adv Radiat Oncol       Date:  2018-05-08

Review 9.  Imaging of Bladder Cancer: Standard Applications and Future Trends.

Authors:  Rasha Taha Abouelkheir; Abdalla Abdelhamid; Mohamed Abou El-Ghar; Tarek El-Diasty
Journal:  Medicina (Kaunas)       Date:  2021-03-01       Impact factor: 2.430

10.  Bladder cancer: do we need contrast injection for MRI assessment of muscle invasion? A prospective multi-reader VI-RADS approach.

Authors:  Andrea Delli Pizzi; Domenico Mastrodicasa; Michele Marchioni; Giulia Primiceri; Francesca Di Fabio; Roberta Cianci; Barbara Seccia; Barbara Sessa; Erica Mincuzzi; Martina Romanelli; Pietro Castellan; Roberto Castellucci; Antonella Colasante; Luigi Schips; Raffaella Basilico; Massimo Caulo
Journal:  Eur Radiol       Date:  2020-11-19       Impact factor: 7.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.